{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:38:26Z","timestamp":1792726706107,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Clinics of North America: Equine Practice"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.cveq.2026.07.012","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:19:18Z","timestamp":1788293958000},"page":"441-455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pituitary Pars Intermedia Dysfunction"],"prefix":"10.1016","volume":"42","author":[{"given":"Sarah A.","family":"Vaughn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey A.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cveq.2026.07.012_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tvjl.2018.03.002","article-title":"Epidemiology of pituitary pars intermedia dysfunction: a systematic literature review of clinical presentation, disease prevalence and risk factors","volume":"235","author":"Ireland","year":"2018","journal-title":"Vet J"},{"issue":"1","key":"10.1016\/j.cveq.2026.07.012_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.2042-3306.2012.00578.x","article-title":"Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses","volume":"45","author":"McGowan","year":"2013","journal-title":"Equine Vet J"},{"issue":"1","key":"10.1016\/j.cveq.2026.07.012_bib3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cveq.2010.12.007","article-title":"Equine pituitary pars Intermedia dysfunction","volume":"27","author":"McFarlane","year":"2011","journal-title":"Veterinary Vet Clin North Am Equine Pract"},{"issue":"1","key":"10.1016\/j.cveq.2026.07.012_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2460\/javma.2003.223.93","article-title":"Demographic and clinical characteristics of geriatric horses: 467 cases (1989\u20131999)","volume":"223","author":"Brosnahan","year":"2003","journal-title":"J Am Vet Med Assoc"},{"issue":"1","key":"10.1016\/j.cveq.2026.07.012_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2460\/javma.2003.223.99","article-title":"Assessment of clinical characteristics, management practices, and activities of geriatric horses","volume":"223","author":"Brosnahan","year":"2003","journal-title":"J Am Vet Med Assoc"},{"issue":"2","key":"10.1016\/j.cveq.2026.07.012_bib6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.cveq.2019.03.005","article-title":"Diagnostic testing for equine endocrine diseases: confirmation versus confusion","volume":"35","author":"McFarlane","year":"2019","journal-title":"Vet Clin N Am Equine Pract"},{"key":"10.1016\/j.cveq.2026.07.012_bib7","article-title":"Recommendations for the diagnosis and management of Pituitary Pars Intermedia Dysfunction (PPID)","author":"Hart","year":"2025","journal-title":"Equine Endocrinology Group"},{"key":"10.1016\/j.cveq.2026.07.012_bib8","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/vetsci9100556","article-title":"Pituitary Pars Intermedia Dysfunction (PPID) in horses","volume":"9","author":"Kirkwood","year":"2022","journal-title":"Vet Sci"},{"issue":"4","key":"10.1016\/j.cveq.2026.07.012_bib9","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1210\/endo-110-4-1430","article-title":"Equine Cushing\u2019s disease: Plasma immunoreactive proopiolipomelanocortin peptide and cortisol levels basally and in response to diagnostic tests","volume":"110","author":"Orth","year":"1982","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.cveq.2026.07.012_bib10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0749-0739(02)00018-4","article-title":"Pituitary pars intermedia dysfunction: equine Cushing\u2019s disease","volume":"18","author":"Schott","year":"2002","journal-title":"Vet Clin N Am Equine Pract"},{"issue":"3","key":"10.1016\/j.cveq.2026.07.012_bib11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.2042-3292.1992.tb01595.x","article-title":"Diagnosis of hyperadrenocorticism in the horse","volume":"4","author":"Hillyer","year":"1992","journal-title":"Equine Vet Educ"},{"issue":"SUPPL. 1","key":"10.1016\/j.cveq.2026.07.012_bib12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1023\/B:VERC.0000045368.38959.8b","article-title":"Equine cushing-like syndrome: diagnosis and therapy in two cases","volume":"28","author":"Sgorgini","year":"2004","journal-title":"Vet Res Commun"},{"key":"10.1016\/j.cveq.2026.07.012_bib13","author":"Schott"},{"issue":"24","key":"10.1016\/j.cveq.2026.07.012_bib14","article-title":"Equine pituitary neoplasia: a clinical report of 21 cases (1990-1992)","volume":"133","author":"van der Kolk","year":"1993","journal-title":"Vet Rec"},{"issue":"1","key":"10.1016\/j.cveq.2026.07.012_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1939-1676.1996.tb02016.x","article-title":"Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism","volume":"10","author":"Cou\u00ebtil","year":"1996","journal-title":"J Vet Intern Med"},{"issue":"6","key":"10.1016\/j.cveq.2026.07.012_bib16","first-page":"742","article-title":"Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (Equine cushing\u2019s disease)","volume":"16","author":"Donaldson","year":"2002","journal-title":"J Vet Intern Med"},{"issue":"4","key":"10.1016\/j.cveq.2026.07.012_bib17","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2746\/042516403776014271","article-title":"Efficacy of trilostane for the treatment of equine Cushing\u2019s syndrome","volume":"35","author":"McGowan","year":"2003","journal-title":"Equine Vet J"},{"issue":"25","key":"10.1016\/j.cveq.2026.07.012_bib18","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/vr.150.25.773","article-title":"Urinary cortisol:creatinine ratios in healthy horses and horses with hyperadrenocorticism and non-adrenal disease","volume":"150","author":"Chandler","year":"2002","journal-title":"Vet Rec"},{"issue":"2","key":"10.1016\/j.cveq.2026.07.012_bib19","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1939-1676.2008.0076.x","article-title":"Cytokine dysregulation in aged horses and horses with pituitary pars Intermedia dysfunction","volume":"22","author":"McFarlane","year":"2008","journal-title":"J Vet Intern Med"},{"issue":"7","key":"10.1016\/j.cveq.2026.07.012_bib20","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2746\/042516402776250333","article-title":"Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing\u2019s disease with cyproheptadine or pergolide","volume":"34","author":"Perkins","year":"2010","journal-title":"Equine Vet J"},{"issue":"2","key":"10.1016\/j.cveq.2026.07.012_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/vr.139.2.41","article-title":"Pergolide treatment for Cushing\u2019s syndrome in a horse","volume":"139","author":"Mu\u00f1oz","year":"1996","journal-title":"Vet Rec"},{"key":"10.1016\/j.cveq.2026.07.012_bib22","series-title":"Aged horse health, management and welfare","author":"McGowan","year":"2008"},{"issue":"12","key":"10.1016\/j.cveq.2026.07.012_bib24","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/avj.13022","article-title":"Circannual variation in plasma adrenocorticotropic hormone concentrations and dexamethasone suppression test results in standardbred horses, Andalusian horses and mixed-breed ponies","volume":"98","author":"Bamford","year":"2020","journal-title":"Aust Vet J"},{"key":"10.1016\/j.cveq.2026.07.012_bib25","doi-asserted-by":"crossref","first-page":"105857","DOI":"10.1016\/j.tvjl.2022.105857","article-title":"The effect of month and breed on plasma adrenocorticotropic hormone concentrations in equids","volume":"286","author":"Durham","year":"2022","journal-title":"Vet J"},{"key":"10.1016\/j.cveq.2026.07.012_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvjl.2023.105995","article-title":"Investigation of breed differences in plasma adrenocorticotropic hormone concentrations among healthy horses and ponies","volume":"296-297","author":"Bamford","year":"2023","journal-title":"Vet J"},{"issue":"1","key":"10.1016\/j.cveq.2026.07.012_bib27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2460\/ajvr.69.1.122","article-title":"Hypertension and insulin resistance in a mixed-breed population of ponies predisposed to laminitis","volume":"69","author":"Bailey","year":"2008","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.cveq.2026.07.012_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jevs.2021.103810","article-title":"Circulating hypothalamic-pituitary-adrenal axis hormones and insulin concentrations in horses and ponies","volume":"111","author":"Vaughn","year":"2022","journal-title":"J Equine Vet Sci"},{"issue":"2","key":"10.1016\/j.cveq.2026.07.012_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/jvim.70047","article-title":"The effect of season and breed on hypothalamic-pituitary-adrenal axis hormones, metabolic hormones, and oxidative markers in ponies and horses","volume":"39","author":"Vaughn","year":"2025","journal-title":"J Vet Intern Med"},{"issue":"7185","key":"10.1016\/j.cveq.2026.07.012_bib30","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature06738","article-title":"Thyrotrophin in the pars tuberalis triggers photoperiodic response","volume":"452","author":"Nakao","year":"2008","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.cveq.2026.07.012_bib31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1530\/ror.0.0010153","article-title":"The pars tuberalis of the pituitary: a gateway for neuroendocrine output","volume":"1","author":"Morgan","year":"1996","journal-title":"Rev Reprod"},{"issue":"4","key":"10.1016\/j.cveq.2026.07.012_bib32","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1152\/physrev.00024.2017","article-title":"POMC: the physiological power of hormone processing","volume":"98","author":"Harno","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1016\/j.cveq.2026.07.012_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-1-61779-204-5_3","article-title":"The proprotein convertases, 20 years later","volume":"768","author":"Seidah","year":"2011","journal-title":"Methods Mol Biol"},{"issue":"3","key":"10.1016\/j.cveq.2026.07.012_bib34","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1210\/endo-110-3-941","article-title":"Proopiolipomelanocortin peptides in normal pituitary, pituitary tumor, and plasma of normal and cushing\u2019s horses","volume":"110","author":"Wilson","year":"1982","journal-title":"Endocrinology"},{"key":"10.1016\/j.cveq.2026.07.012_bib35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1939-1676.2005.tb02685.x","article-title":"Variation in plasma adrenocorticotropic hormone concentration and dexamethasone suppression test results with season, age, and sex in healthy ponies and horses","volume":"19","author":"Donaldson","year":"2005","journal-title":"J Vet Intern Med"},{"issue":"1","key":"10.1016\/j.cveq.2026.07.012_bib36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.2042-3306.2012.00575.x","article-title":"Evaluation of basal plasma \u03b1-melanocyte-stimulating hormone and adrenocorticotrophic hormone concentrations for the diagnosis of pituitary pars intermedia dysfunction from a population of aged horses","volume":"45","author":"McGowan","year":"2013","journal-title":"Equine Vet J"},{"issue":"4","key":"10.1016\/j.cveq.2026.07.012_bib37","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.2042-3306.2011.00444.x","article-title":"Circannual variation in plasma adrenocorticotropic hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction","volume":"44","author":"Copas","year":"2012","journal-title":"Equine Vet J"},{"issue":"5","key":"10.1016\/j.cveq.2026.07.012_bib38","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1111\/jvim.14782","article-title":"The effect of geographic location on circannual adrenocorticotropic hormone plasma concentrations in horses in Australia","volume":"31","author":"Secombe","year":"2017","journal-title":"J Vet Intern Med"},{"issue":"8","key":"10.1016\/j.cveq.2026.07.012_bib39","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1365-2826.2008.01751.x","article-title":"Seasonal changes in circadian peripheral plasma concentrations of melatonin, serotonin, dopamine and cortisol in aged horses with cushing\u2019s disease under natural photoperiod","volume":"20","author":"Haritou","year":"2008","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"10.1016\/j.cveq.2026.07.012_bib40","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1939-1676.2010.0500.x","article-title":"Seasonal variation in serum concentrations of selected metabolic hormones in horses","volume":"24","author":"Place","year":"2010","journal-title":"J Vet Intern Med"},{"issue":"4","key":"10.1016\/j.cveq.2026.07.012_bib41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.domaniend.2012.05.005","article-title":"Circadian and circannual rhythms of cortisol, ACTH, and \u03b1-melanocyte-stimulating hormone in healthy horses","volume":"43","author":"Cordero","year":"2012","journal-title":"Domest Anim Endocrinol"},{"key":"10.1016\/j.cveq.2026.07.012_bib42","series-title":"Dopamine - Health and disease","first-page":"87","article-title":"Physiology and metabolic anomalies of dopamine in horses: a review","author":"Ambrojo","year":"2018"},{"issue":"2","key":"10.1016\/j.cveq.2026.07.012_bib43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2826.2005.01277.x","article-title":"Nitration and increased alpha-Synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars Intermedia dysfunction","volume":"17","author":"McFarlane","year":"2005","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.cveq.2026.07.012_bib44","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.rvsc.2022.08.018","article-title":"Correlation of pituitary histomorphometry with dopamine and dopamine D2 receptor expression in horses with pituitary pars intermedia dysfunction","volume":"152","author":"Huang","year":"2022","journal-title":"Res Vet Sci"},{"issue":"3","key":"10.1016\/j.cveq.2026.07.012_bib45","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jevs.2009.01.004","article-title":"Extrapituitary and pituitary pathological findings in horses with pituitary pars intermedia dysfunction: a retrospective study","volume":"29","author":"Glover","year":"2009","journal-title":"J Equine Vet Sci"},{"issue":"6","key":"10.1016\/j.cveq.2026.07.012_bib46","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/030098589902700606","article-title":"Immunocytochemical demonstration of proopiomelanocortin-derived peptides in pituitary adenomas of the pars intermedia in horses","volume":"27","author":"Heinrichs","year":"1990","journal-title":"Vet Pathol"},{"issue":"1","key":"10.1016\/j.cveq.2026.07.012_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190796","article-title":"Profiles of pro-opiomelanocortin and encoded peptides, and their processing enzymes in equine pituitary pars intermedia dysfunction","volume":"13","author":"Carmalt","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cveq.2026.07.012_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/jvimsj\/aalag023","article-title":"Associations among beta-endorphin, ACTH, cortisol concentration, age, and clinical signs indicative of pituitary pars intermedia dysfunction in geriatric horses","volume":"40","author":"Billmann","year":"2026","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.cveq.2026.07.012_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.domaniend.2025.106982","article-title":"Pilot study of \u03b2-endorphin concentrations in horses with pituitary pars intermedia dysfunction using a newly validated enzyme-linked immunosorbent assay","volume":"95","author":"Fouch\u00e9","year":"2026","journal-title":"Domest Anim Endocrinol"},{"issue":"2","key":"10.1016\/j.cveq.2026.07.012_bib50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0021-9975(08)80260-5","article-title":"Equine pituitary adenoma: a functional and morphological study","volume":"109","author":"Boujon","year":"1993","journal-title":"J Comp Pathol"},{"issue":"4","key":"10.1016\/j.cveq.2026.07.012_bib51","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/eve.12160","article-title":"Pituitary pars intermedia dysfunction: diagnosis and treatment","volume":"26","author":"Durham","year":"2014","journal-title":"Equine Vet Educ"},{"issue":"8","key":"10.1016\/j.cveq.2026.07.012_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/vetsci12080780","article-title":"Equine pituitary pars intermedia dysfunction","volume":"12","author":"Menzies-Gow","year":"2025","journal-title":"Vet Sci"},{"key":"10.1016\/j.cveq.2026.07.012_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvjl.2023.106036","article-title":"Diagnosis of equine pituitary pars intermedia dysfunction","volume":"300-302","author":"Stewart","year":"2023","journal-title":"Vet J"},{"key":"10.1016\/j.cveq.2026.07.012_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.domaniend.2025.106959","article-title":"Investigation of peptide cross reactivity in equine plasma using two adrenocorticotropic hormone immunoassays","volume":"93","author":"Durham","year":"2025","journal-title":"Domest Anim Endocrinol"},{"issue":"1","key":"10.1016\/j.cveq.2026.07.012_bib55","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/vcp.12326","article-title":"Initial analytic quality assessment and method comparison of an immunoassay for adrenocorticotropic hormone measurement in equine samples","volume":"45","author":"Irvine","year":"2016","journal-title":"Vet Clin Pathol"},{"key":"10.1016\/j.cveq.2026.07.012_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.domaniend.2023.106785","article-title":"Short communication: identification of equine corticotropin-like intermediate lobe peptide (CLIP) binding to an adrenocortipcotrophic hormone (ACTH) assay capture antibody","volume":"83","author":"Knowles","year":"2023","journal-title":"Domest Anim Endocrinol"},{"issue":"3","key":"10.1016\/j.cveq.2026.07.012_bib57","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/104063879700900307","article-title":"Validation of nonradioactive chemiluminescent immunoassay methods for the analysis of thyroxine and cortisol in blood samples obtained from dogs, cats, and horses","volume":"9","author":"Singh","year":"1997","journal-title":"J Vet Diagn Invest"},{"key":"10.1016\/j.cveq.2026.07.012_bib58","author":"Hart"},{"issue":"2","key":"10.1016\/j.cveq.2026.07.012_bib59","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/evj.14009","article-title":"BEVA primary care clinical guidelines: diagnosis and management of equine pituitary pars intermedia dysfunction","volume":"56","author":"Menzies-Gow","year":"2024","journal-title":"Equine Vet J"},{"key":"10.1016\/j.cveq.2026.07.012_bib60","first-page":"300","article-title":"Evaluation of seasonal influences on adrenocorticotropic hormone response to the thyrotropin-releasing hormone stimulation test and its accuracy for diagnosis of pituitary pars intermedia dysfunction","author":"Adams","year":"2023","journal-title":"Vet J"},{"key":"10.1016\/j.cveq.2026.07.012_bib61","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.domaniend.2014.02.004","article-title":"Influence of feeding status, time of the day, and season on baseline adrenocorticotropic hormone and the response to thyrotropin releasing hormone-stimulation test in healthy horses","volume":"48","author":"Diez De Castro","year":"2014","journal-title":"Domest Anim Endocrinol"},{"key":"10.1016\/j.cveq.2026.07.012_bib62","doi-asserted-by":"crossref","DOI":"10.1111\/j.1939-1676.2011.0712.x","article-title":"Seasonal changes in plasma adrenocorticotropic hormone and a-Melanocyte-Stimulating hormone in response to thyrotropin-releasing hormone in normal, aged horses","author":"Funk","year":"2011","journal-title":"J Vet Intern Med"},{"issue":"6","key":"10.1016\/j.cveq.2026.07.012_bib63","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1111\/jvim.16281","article-title":"Repeatability of a thyrotropin-releasing hormone stimulation test for diagnosis of pituitary pars intermedia dysfunction in mature horses","volume":"35","author":"Kam","year":"2021","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.cveq.2026.07.012_bib64","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.tvjl.2018.07.008","article-title":"Circannual variability in adrenocorticotropic hormone responses to administration of thyrotropin-releasing hormone in clinically normal horses in Australia","volume":"238","author":"Byrne","year":"2018","journal-title":"Vet J"},{"key":"10.1016\/j.cveq.2026.07.012_bib65","doi-asserted-by":"crossref","DOI":"10.1111\/evj.14468","article-title":"Effect of pergolide treatment on insulin dysregulation in horses and ponies with pituitary pars intermedia dysfunction","author":"Galinelli","year":"2025","journal-title":"Equine Vet J"},{"key":"10.1016\/j.cveq.2026.07.012_bib66","article-title":"Recommendations for the diagnosis and management of Equine Metabolic Syndrome (EMS) and insulin dysregulation","author":"Bertin","year":"2024","journal-title":"Equine Endocrinology Group"},{"issue":"5","key":"10.1016\/j.cveq.2026.07.012_bib67","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1111\/jvim.15601","article-title":"Effect of thyrotropin-releasing hormone stimulation testing on the oral sugar test in horses when performed as a combined protocol","volume":"33","author":"Hodge","year":"2019","journal-title":"J Vet Intern Med"},{"issue":"7","key":"10.1016\/j.cveq.2026.07.012_bib68","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2460\/ajvr.77.7.738","article-title":"Effects of withholding feed on thyrotropin-releasing hormone stimulation test results and effects of combined testing on oral sugar test and thyrotropin-releasing hormone stimulation test results in horses","volume":"77","author":"Restifo","year":"2016","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.cveq.2026.07.012_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvjl.2022.105831","article-title":"The effect of pergolide mesylate on adrenocorticotrophic hormone responses to exogenous thyrotropin releasing hormone in horses","volume":"285","author":"Durham","year":"2022","journal-title":"Vet J"},{"issue":"2","key":"10.1016\/j.cveq.2026.07.012_bib70","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/jvp.12339","article-title":"Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction","volume":"40","author":"McFarlane","year":"2017","journal-title":"J Vet Pharmacol Therapeut"},{"key":"10.1016\/j.cveq.2026.07.012_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.domaniend.2020.106531","article-title":"Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses","volume":"74","author":"Miller","year":"2021","journal-title":"Domest Anim Endocrinol"},{"issue":"3","key":"10.1016\/j.cveq.2026.07.012_bib72","doi-asserted-by":"crossref","DOI":"10.1111\/jvim.70109","article-title":"Long-term response of equids with pituitary pars Intermedia dysfunction to treatment with pergolide","volume":"39","author":"Schott","year":"2025","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.cveq.2026.07.012_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvjl.2022.105899","article-title":"Management of pituitary pars intermedia dysfunction in practice: a clinical audit","volume":"289","author":"Steel","year":"2022","journal-title":"Vet J"},{"key":"10.1016\/j.cveq.2026.07.012_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvjl.2020.105562","article-title":"Efficacy of pergolide for the management of equine pituitary pars intermedia dysfunction: a systematic review","volume":"266","author":"Tatum","year":"2020","journal-title":"Vet J"},{"key":"10.1016\/j.cveq.2026.07.012_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2024.1332337","article-title":"Retrospective assessment of the use of extended-release cabergoline in the management of equine pituitary pars intermedia dysfunction","volume":"11","author":"Sundra","year":"2024","journal-title":"Front Vet Sci"},{"issue":"6","key":"10.1016\/j.cveq.2026.07.012_bib76","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/j.1939-1676.2012.00994.x","article-title":"A comparative review of vitamin E and associated equine disorders","volume":"26","author":"Finno","year":"2012","journal-title":"J Vet Intern Med"},{"issue":"6","key":"10.1016\/j.cveq.2026.07.012_bib77","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/evj.12692","article-title":"Effects of feeding two RRR-\u03b1-tocopherol formulations on serum, cerebrospinal fluid and muscle \u03b1-tocopherol concentrations in horses with subclinical vitamin E deficiency","volume":"49","author":"Brown","year":"2017","journal-title":"Equine Vet J"},{"issue":"6","key":"10.1016\/j.cveq.2026.07.012_bib78","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2460\/ajvr.71.6.664","article-title":"Gene expression of proteolytic systems and growth regulators of skeletal muscle in horses with myopathy associated with pituitary pars intermedia dysfunction","volume":"71","author":"Aleman","year":"2010","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.cveq.2026.07.012_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.domaniend.2021.106620","article-title":"Markers of muscle atrophy and impact of treatment with pergolide in horses with pituitary pars intermedia dysfunction and muscle atrophy","volume":"76","author":"Banse","year":"2021","journal-title":"Domest Anim Endocrinol"},{"key":"10.1016\/j.cveq.2026.07.012_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.jevs.2021.103771","article-title":"Development and evaluation of a Muscle Atrophy Scoring System (MASS) for horses","volume":"110","author":"Herbst","year":"2022","journal-title":"J Equine Vet Sci"},{"issue":"23","key":"10.1016\/j.cveq.2026.07.012_bib81","article-title":"Plasma amino acids in horses suffering from pituitary pars Intermedia dysfunction","volume":"12","author":"Stoeckle","year":"2022","journal-title":"Animals (Basel)"},{"key":"10.1016\/j.cveq.2026.07.012_bib82","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.tvjl.2018.03.007","article-title":"Fecal strongyle egg counts in horses with suspected pre-clinical pituitary pars intermedia dysfunction before and after treatment with pergolide","volume":"235","author":"Christen","year":"2018","journal-title":"Vet J"},{"key":"10.1016\/j.cveq.2026.07.012_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.vetpar.2024.110176","article-title":"Strongyle egg shedding and egg reappearance periods in horses with pituitary pars intermedia dysfunction","volume":"328","author":"Horner","year":"2024","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.cveq.2026.07.012_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.vetpar.2024.110182","article-title":"Ivermectin performance in horses diagnosed with equine endocrine disorders","volume":"328","author":"Nielsen","year":"2024","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.cveq.2026.07.012_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2023.1114445","article-title":"Periodontal structures in horses with pituitary pars intermedia dysfunction: a histological evaluation","volume":"10","author":"Zapf","year":"2023","journal-title":"Front Vet Sci"},{"issue":"4","key":"10.1016\/j.cveq.2026.07.012_bib86","doi-asserted-by":"crossref","first-page":"511","DOI":"10.5455\/OVJ.2022.v12.i4.14","article-title":"Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis","volume":"12","author":"Kellon","year":"2022","journal-title":"Open Vet J"},{"issue":"6","key":"10.1016\/j.cveq.2026.07.012_bib87","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1111\/jvim.16906","article-title":"Short-term effects of canagliflozin on glucose and insulin responses in insulin dysregulated horses: a randomized, placebo-controlled, double-blind, study","volume":"37","author":"Lind\u00e5se","year":"2023","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.cveq.2026.07.012_bib88","first-page":"1","article-title":"Bexagliflozin controls hyperinsulinemia in horses with naturally occurring insulin dysregulation: a placebo-controlled crossover trial","author":"Lowndes","year":"2026","journal-title":"J Am Vet Med Assoc"},{"issue":"9","key":"10.1016\/j.cveq.2026.07.012_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203655","article-title":"The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies","volume":"13","author":"Meier","year":"2018","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"10.1016\/j.cveq.2026.07.012_bib90","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/jvp.13470","article-title":"Sodium-glucose transport protein 2 inhibitor use in the management of insulin dysregulation in ponies and horses","volume":"48 Suppl 1","author":"Menzies-Gow","year":"2025","journal-title":"J Vet Pharmacol Therapeut"},{"key":"10.1016\/j.cveq.2026.07.012_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvjl.2025.106412","article-title":"Canagliflozin: pharmacokinetics, tolerability and glucose\/insulin effects of supratherapeutic doses in healthy horses","volume":"313","author":"Michanek","year":"2025","journal-title":"Vet J"},{"key":"10.1016\/j.cveq.2026.07.012_bib92","doi-asserted-by":"crossref","DOI":"10.1002\/evj.70150","article-title":"Treatment with ertugliflozin mitigates the hyperinsulinemic response to intra-articular triamcinolone acetonide","author":"Page","year":"2026","journal-title":"Equine Vet J"},{"key":"10.1016\/j.cveq.2026.07.012_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.domaniend.2024.106894","article-title":"Short-term clinical and biochemical responses following treatment with dapagliflozin or ertugliflozin in horses with hyperinsulinemia: a retrospective case series","volume":"90","author":"Sundra","year":"2025","journal-title":"Domest Anim Endocrinol"},{"issue":"6","key":"10.1016\/j.cveq.2026.07.012_bib94","doi-asserted-by":"crossref","DOI":"10.1111\/jvim.70256","article-title":"Effects of the sodium-glucose Cotransporter-2 inhibitor velagliflozin on insulin concentrations in horses with insulin dysregulation","volume":"39","author":"Thane","year":"2025","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.cveq.2026.07.012_bib95","doi-asserted-by":"crossref","DOI":"10.1002\/evj.70181","article-title":"Short-term clinical responses in horses and ponies treated with canagliflozin: a clinical field study","author":"H\u00e4llbom","year":"2026","journal-title":"Equine Vet J"}],"container-title":["Veterinary Clinics of North America: Equine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749073926000593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749073926000593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:00:31Z","timestamp":1792724431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749073926000593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":94,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0749073926000593"],"URL":"https:\/\/doi.org\/10.1016\/j.cveq.2026.07.012","relation":{},"ISSN":["0749-0739"],"issn-type":[{"value":"0749-0739","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pituitary Pars Intermedia Dysfunction","name":"articletitle","label":"Article Title"},{"value":"Veterinary Clinics of North America: Equine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cveq.2026.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}